Ansamitocin P3 Depolymerizes Microtubules and Induces Apoptosis by Binding to Tubulin at the Vinblastine Site

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Venghateri, Jubina B ^a   Gupta, Tilak Kumar ^a   Verma, Paul J ^b   Kunwar, Ambarish ^a   Panda, Dulal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMITOCIN P 3; BUB1 RELATED PROTEIN; CYSTEINE; MAYTANSINE; PROTEIN MAD2; PROTEIN P53; TUBULIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DEPOLYMERIZATION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INTERPHASE; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE; MINIMUM INHIBITORY CONCENTRATION; MITOSIS; MOLECULAR DOCKING; MOLECULAR STABILITY; PROTEIN CONFORMATION;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; HELA CELLS; HUMANS; MAYTANSINE; MICROSCOPY, FLUORESCENCE; MICROTUBULES; TUBULIN; VINBLASTINE;

EID: 84885050645     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075182     Document Type: Article

References (54)

1. Sievers EL, Senter PD, (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64: 15-29.
2. Liu C, Chari RV, (1997) The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin Investig Drugs 6: 169-172.
3. Cassady JM, Chan KK, Floss HG, Leistner E, (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 52: 1-26.
4. Issell BF, Crooke ST, (1978) Maytansine. Cancer Treat Rev 5: 199-207.
5. Ikeyama S, Takeuchi M, (1981) Antitubulin activities of ansamitocins and maytansinoids. Biochem Pharmacol 30: 2421-2425.
6. Sieber SM, Wolpert MK, Adamson RH, Cysyk RL, Bono VH, et al. (1975) Experimental studies with maytansine-a new antitumor agent. Bibl Haematol: 495-500.
7. Remillard S, Rebhun LI, Howie GA, Kupchan SM, (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189: 1002-1005.
8. Huang AB, Lin CM, Hamel E, (1985) Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. Biochem Biophys Res Commun 128: 1239-1246.
9. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, et al. (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9: 2689-2699.
10. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, et al. (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9: 2700-2713.
11. Tanida S, Hasegawa T, Hatano K, Higashide E, Yoneda M, (1980) Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. J Antibiot (Tokyo) 33: 192-198.
12. Higashide E, Asai M, Ootsu K, Tanida S, Kozai Y, et al. (1977) Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature 270: 721-722.
13. Kupchan SM, Komoda Y, Branfman AR, Sneden AT, Court WA, et al. (1977) The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem 42: 2349-2357.
14. Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, et al. (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94: 1354-1356.
15. Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, et al. (1978) Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem 21: 31-37.
16. Hamel E, (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther. 55: 31-51.
17. Li Y, Kobayashi H, Hashimoto Y, Iwasaki S, (1992) Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. Biochem Biophys Res Commun 187: 722-729.
18. Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, et al. (1987) Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta 926: 215-223.
19. Rai A, Surolia A, Panda D, (2012) An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics. PLoS One 7: e44311.
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
21. Mohan R, Panda D, (2008) Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest. Cancer Res 68: 6181-6189.
22. Rathinasamy K, Panda D, (2008) Kinetic stabilization of microtubule dynamic instability by benomyl increases the nuclear transport of p53. Biochem Pharmacol 76: 1669-1680.
23. Gajula PK, Asthana J, Panda D, Chakraborty TK, (2013) A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death. J Med Chem 56: 2235-2245.
24. Hamel E, Lin CM, (1981) Glutamate-induced polymerization of tubulin: characteristics of the reaction and application to the large-scale purification of tubulin. Arch Biochem Biophys 209: 29-40.
25. Gupta K, Panda D, (2002) Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry 41: 13029-13038.
26. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
27. Ellman GL, (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77.
28. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
29. Rai A, Gupta TK, Kini S, Kunwar A, Surolia A, et al. (2013) CXI-benzo-84 reversibly binds to tubulin at colchicine site and induces apoptosis in cancer cells. Biochem Pharmacol 86: 378-391.
30. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
31. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, et al. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435: 519-522.
32. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
33. Hetenyi C, van der Spoel D, (2006) Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett 580: 1447-1450.
34. Iorga B, Herlem D, Barre E, Guillou C, (2006) Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. Journal of Molecular Modeling 12: 366-372.
35. Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, et al. (2011) Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem Pharmacol 81: 723-735.
36. May KM, Hardwick KG, (2006) The spindle checkpoint. J Cell Sci 119: 4139-4142.
37. Chaitanya GV, Steven AJ, Babu PP, (2010) PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8: 31.
38. Luduena RF, Roach MC, (1991) Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther 49: 133-152.
39. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG, (1976) Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72: 47-54.
40. Bhattacharyya B, Wolff J, (1977) Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 75: 159-162.
41. Kukol A (2008) Molecular modeling of proteins. Totowa, NJ: Humana Press.
42. Hubbard SJ and Thornton JM (1996) NACCESS Computer Program, version 2.1.1,Department of Biochemisry and Molecular Biology, University College London, London.
43. Mills JE, Dean PM, (1996) Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J Comput Aided Mol Des 10: 607-622.
44. Babu MM, (2003) NCI: A server to identify non-canonical interactions in protein structures. Nucleic Acids Res 31: 3345-3348.
45. Kaur H, Raghava GP, (2006) Prediction of C alpha-H.O and C alpha-H.pi interactions in proteins using recurrent neural network. In Silico Biol 6: 111-125.
46. Suezawa H, Ishihara S, Umezawa Y, Tsuboyama S, Nishio M, (2004) The Aromatic CH/π Hydrogen Bond as an Important Factor in Determining the Relative Stability of Diastereomeric Salts Relevant to Enantiomeric Resolution - A Crystallographic Database Study. European Journal of Organic Chemistry 2004: 4816-4822.
47. Riley KE, Hobza P, (2011) Strength and Character of Halogen Bonds in Protein-Ligand Complexes. Crystal Growth & Design 11: 4272-4278.
48. Auffinger P, Hays FA, Westhof E, Ho PS, (2004) Halogen bonds in biological molecules. Proc Natl Acad Sci U S A 101: 16789-16794.
49. Taft F, Harmrolfs K, Nickeleit I, Heutling A, Kiene M, et al. (2012) Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. Chemistry 18: 880-886.
50. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L, (1998) Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc Natl Acad Sci U S A 95: 9313-9318.
51. Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, et al. (2000) Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 39: 14121-14127.
52. Lobert S, Frankfurter A, Correia JJ, (1995) Binding of vinblastine to phosphocellulose-purified and alpha beta-class III tubulin: the role of nucleotides and beta-tubulin isotypes. Biochemistry 34: 8050-8060.
53. Daly EM, Taylor RE, (2009) Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents. Current Chemical Biology 3: 367-379.
54. Bhattacharyya B, Wolff J, (1976) Tubulin aggregation and disaggregation: mediation by two distinct vinblastine-binding sites. Proc Natl Acad Sci U S A 73: 2375-2378.